Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ6 | P48051 | 8/20 | 0.51 |
| ▸ | KCNJ3 | P48549 | 8/20 | 0.51 |
| ▸ | KCNJ5 | P48544 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4867428 | 0.83 | MEN1 (0.51) | KCNJ6KCNJ3KCNJ5MEN1KMT2A | |
| SCHEMBL4867905 | 0.81 | ALDH1A1 (0.53) | KCNJ6KCNJ3KCNJ5MEN1KMT2A | |
| SCHEMBL4870057 | 0.80 | HPGD (0.59) | KCNJ6KCNJ3MEN1KMT2AHTT | |
| SCHEMBL4868299 | 0.78 | MEN1 (0.45) | KCNJ6KCNJ3KCNJ5MEN1KMT2A | |
| SCHEMBL4864524 | 0.77 | MEN1 (0.56) | KCNJ6KCNJ3MEN1KMT2AHTT | |
| SCHEMBL5848714 | 0.76 | POLB (0.43) | MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL5848152 | 0.76 | POLB (0.43) | MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL5849886 | 0.75 | ALDH1A1 (0.45) | MEN1KMT2APKMALDH1A1GAA | |
| SCHEMBL14158096 | 0.75 | MEN1 (0.52) | KCNJ6KCNJ3MEN1KMT2AHTT | |
| SCHEMBL4912638 | 0.75 | MEN1 (0.52) | KCNJ6KCNJ3MEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900207-B2 | N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-31 | — | — | US | claimed |
| US-20030153508-A1 | Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-08-14 | — | — | US | claimed |
| EP-1254901-A1 | NITROGEN-CONTAINING 5-MEMBERED CYCLIC COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-11-06 | — | — | EP | claimed |
| US-7390804-B2 | N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-24 | — | — | US | disclosed |
| US-7390804-B2 | N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-24 | — | — | US | disclosed |
| US-7390804-B2 | N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-24 | — | — | US | disclosed |
| US-20050164954-A1 | N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2005-07-28 | — | — | US | disclosed |
| US-6900207-B2 | N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-31 | — | — | US | disclosed |
| US-20030153508-A1 | Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-08-14 | — | — | US | disclosed |
| EP-1254901-A1 | NITROGEN-CONTAINING 5-MEMBERED CYCLIC COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050164954-A1 | N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient | ACIN1, CASP7, CASP10 | KCNJ6 4425/4885KCNJ3 4389/4885KCNJ5 3890/4885 |
| US-20030153508-A1 | Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient | ACIN1, CASP7, CASP10 | KCNJ6 4343/4885KCNJ3 4291/4885KCNJ5 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.